Liquidia Corporation (LQDA)

Liquidia Corp.'s stock has shown significant positive momentum over the past six months, with a 157.80% increase from January 6, 2025, to January 2, 2026, and a 170.14% increase over the past six months. The stock surged over 18% on January 9, 2026. While the stock was up approximately 28% over the past three months, it experienced an 11% loss over the past month as of January 8, 2026. Key events impacting the stock price include the FDA approval of YUTREPIA in May 2025, the successful commercial launch of YUTREPIA with strong initial demand, analyst upgrades and price target revisions, and notable insider selling of LQDA shares.

Liquidia Corp.'s product, YUTREPIA, demonstrates a strong and growing demand trend rather than distinct seasonality at this early stage of its commercialization. Since its launch in June 2025, YUTREPIA has shown continued strong demand with quarter-over-quarter growth in net product sales. The company has reported rapid uptake, indicating robust market acceptance.

Liquidia Corp. is a biopharmaceutical company focused on developing, manufacturing, and commercializing products for rare cardiopulmonary diseases. It operates in the Healthcare sector and Biotechnology industry, utilizing its PRINT technology to create uniform drug particles for improved drug delivery. Its main products include YUTREPIA (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), Remodulin, and L606, an investigational liposomal formulation of treprostinil.

Liquidia Corp. primarily develops, manufactures, and commercializes its products in the United States. The company conducts its clinical research predominantly within the U.S. and is headquartered in Morrisville, North Carolina.

Liquidia Corp.'s brand reputation has been positively influenced by the successful FDA approval and commercial launch of YUTREPIA. The strong initial demand, rapid patient adoption, and better-than-expected sales figures have boosted investor confidence. Ongoing litigation with United Therapeutics regarding patents related to treprostinil introduces an element of risk and uncertainty.

Liquidia Corp. has a mixed ownership structure. Institutional investors hold a significant portion, ranging from approximately 57% to 64.54% of the company's stock. Insiders own between 22.64% and 30.10% of the stock. The general public/retail investors hold approximately 9.20% to 20.09% of the shares.